Systemic sclerosis & Raynaud's
Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis–Associated Interstitial Lung Disease
Authors' conclusion
With several potential biomarkers of progressive disease in patients, the next step includes validation in larger, multicenter cohorts for use in clinical decision-making.
Study context
- Population
- Patients with SSc-ILD, progressive or stable, and control participants
- Comparison
- Progressive SSc-ILD vs stable SSc-ILD
- Controlsn = 6
- Outcome
- Gene signatures predicting progressive interstitial lung disease (ILD)
Methodological detailsbulk and single-cell peripheral blood mononuclear cell (PBMC) RNA gene expression, comparison with previously identified serum biomarkers
- Bulk and single-cell PBMC RNA gene expression
- Comparison with previously identified serum biomarkers
Main finding
As reported in the abstract
Gene expression predictive of progressive SSc-ILD
- Monocyte LOXHD1 and RHOB expression strongly predicted progression
- LOXHD1 and related genes enriched in inflammatory gene networks
- RHOB consistently up-regulated in CD14+ and CD16+ monocytes across single-cell and bulk RNA data
- ATXN2L down-regulated in progressive disease
- S100A12, CHI3L1 and MMP9 associated with progression in bulk RNA sequencing and previous microarray studies
Further findings
Previously identified predictors of progressive disease
- Male sex, Krebs von den Lungen 6 levels and CRP levels were predictors of progressive disease in previous studies
Original publication
Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis–Associated Interstitial Lung Disease. Arthritis Care Res (Hoboken). Published 29 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →